Home Page - SFB 1479 - OncoEscape

Oncogene-driven immune escape (OncoEscape)
Collaborative Research Centre 1479

The Collaborative Research Center (CRC) 1479 “Oncogene-driven immune escape” is a research consortium of clinical and basic tumor biologists and immunologist. Our CRC builds on the scientific hypothesis that oncogenic signalling and immune escape mechanisms are closely connected. This concept implies that targeting of oncogene-driven immune evasion could take treatment beyond palliative therapy towards cures for different types of cancer.

Our Research Program

Principal Investigators

Principal Investigators

Projects

Projects

Early Career Support

Early Career Support

Frau Prof. Börries erhält den Deutschen Krebspreis 2025

Apr 14, 2025 – Mit medizinischer Bioinformatik hin zu personalisierter Krebstherapie. Professorin Melanie Börries wird für ihre herausragenden Leistungen in der molekularen Onkologie und personalisierten Medizin mit dem Deutschen Krebspreis in der Kategorie „Translationale...

The Jon van Rood award for 2025 goes to Janaki Vinnakota

Apr 02, 2025 – The prestigious Jon J. van Rood Award honors outstanding contributions in the field of hematopoietic transplantation immunology, like graft-vs-leukaemia/tumour effects, or development of innovative therapeutic approaches based on the engineering...

CRC 1479 scientist receives prestigious Donnall Thomas Lecture Prize

Feb 15, 2025 – Prof. Dr. Robert Zeiser (P01) has been honored with the esteemed Donnall Thomas Lecture Prize by the American Society for Transplantation and Cellular Therapy. This prestigious award, presented in February...

More News

Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.

Gorantla SP, Rassner M, Crossley KA, Müller TA, Poggio T, Khaja Saleem S, Kleinfelder H, Gambheer SMM, Endres C, Schaberg S, Schmidt D, Prince G, Gonzalez-Menendez I, Bentrop D, Trittler R, Rylova S, Pfeifer D, Andrieux G, Quintanilla-Martinez L, Illert AL, von Bubnoff N, Zeiser R, Duyster J. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6.

Ho NHJG, Talvard-Balland N, Köhler N, Zeiser R. Immune Escape of Acute Myeloid Leukemia after Transplantation. Blood Cancer Discov. 2025 May 5;6(3):168-181. doi: 10.1158/2643-3230.BCD-24-0063.

More Publications